ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
A key tool for monitoring breast cancer patients under neoadjuvant treatment is the identification of reliable predictive markers. Ki67 has been identified as a prognostic and predictive marker in ER-positive breast cancer. Ninety ER-positive, HER2 negative locally advanced breast cancer patients re...
Main Authors: | A Ianza, F Giudici, C Pinello, SP Corona, C Strina, O Bernocchi, M Bortul, M Milani, M Sirico, G Allevi, S Aguggini, A Cocconi, C Azzini, M Dester, V Cervoni, A Bottini, M Cappelletti, D Generali |
---|---|
Format: | Article |
Language: | English |
Published: |
IOS Press
2020-06-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428320925301 |
Similar Items
-
Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
by: Anna Ianza, et al.
Published: (2021-03-01) -
Early Changes of the Standardized Uptake Values (SUV<sub>max</sub>) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
by: Marianna Sirico, et al.
Published: (2020-11-01) -
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
by: Ottavia Bernocchi, et al.
Published: (2021-02-01) -
Novel letrozole dosing: is a single dose of letrozole equivalent to traditional 5-day dosing?
by: Caitlin E. Martin, M.D., M.S.
Published: (2020-12-01) -
A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
by: Aphinives P, et al.
Published: (2015-01-01)